on OXURION (EBR:OXUR)
Oxurion launches Exagis' eTMF module to optimize clinical trials
Oxurion NV, a biopharmaceutical company based in Leuven, has announced the commercial launch of its eTMF module, a key component of its Exagis platform. This development reinforces their strategy of creating a modular and comprehensive eClinical solution.
The eTMF (electronic Trial Master File) module aims to centralize essential clinical trial documentation. It is designed to improve regulatory compliance and facilitate collaboration among stakeholders. It contributes to improved operational efficiency and oversight of clinical trials.
Exagis was developed by Axiodis CRO, a subsidiary of Oxurion, leveraging proven clinical expertise. The eTMF module represents a significant milestone for the platform, and further features integrating artificial intelligence and operational analytics are planned for the future.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news